Alzamend Neuro Inc
NASDAQ: ALZN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stephan Jackman
- Employees
- 5
- Headquarters
- Atlanta, United States
- IPO year
- 2021
- Market cap
- $4.3M
- Website
- https://www.alzamend.com
Loading ALZN…
Loading profile data…Frequently asked questions about ALZN
What does Alzamend Neuro Inc (ALZN) do?
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic st...
Where does ALZN trade?
Alzamend Neuro Inc (ALZN) trades on the NASDAQ.
What sector is ALZN in?
Alzamend Neuro Inc (ALZN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Alzamend Neuro Inc?
Stephan Jackman is the chief executive officer of Alzamend Neuro Inc (ALZN).
Where is Alzamend Neuro Inc headquartered?
Alzamend Neuro Inc is headquartered in United States.
Does ALZN pay a dividend?
Alzamend Neuro Inc (ALZN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALZN go public?
Alzamend Neuro Inc (ALZN) completed its initial public offering in 2021.